KPNA2 silencing sensitizes triple-negative breast cancer to chemotherapy by promoting multipolar division and suppressing DNA damage repair.
KPNA2 silencing sensitizes triple-negative breast cancer to chemotherapy by promoting multipolar division and suppressing DNA damage repair.
Yufan Cai,Jun-Ze Du,12 Authors,Wei Zhu
2025 · DOI: 10.1038/s41388-025-03503-z
Oncogene · 0 Citations
TLDR
This study analyzed breast cancer data from The Cancer Genome Atlas and discovered that KPNA2 was significantly overexpressed in the basal subtype of the PAM50 classification, providing compelling evidence supporting KPNA2 as a promising therapeutic target for overcoming chemoresistance in TNBC.